GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Susmed 4263.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

263

-4.71%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Susmed

Its shares trade on Tokyo Stock Exchange under the ticker 4263.T. It has been listed since 24 December 2021. In the fiscal year to 30 June 2026, it reported revenue of ¥497.2m and a net loss of ¥382.7m. At that date it held total assets of ¥4.22bn and shareholders' equity of ¥4.07bn.

SUSMED, Inc. engages in the development of therapeutic applications. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-12-24. The firm operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Technology
Listed since
24 Dec 2021
Employees
33

Leadership

Pay as last reported

  • Mr. Taro UenoPresident, Representative Director, since 2016
  • Mr. Yusuke YajimaChief Operating Officer, Director, since 2020
  • Mr. Tomomitsu MotohashiChief Technology Officer, Director, since 2019
  • Mr. Takayuki OharaDirector, since 2020
  • Mr. Kuniaki KagaIndependent Director
  • Mr. Yasuhiro YamadaIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Develops therapeutic applications for insomnia, breast cancer, and chronic kidney diseases.
  • Operates through two business segments: DTx Product and DTx Platform.
  • Has a focused workforce of 33 full-time employees in Tokyo-To.

Weaknesses

  • Limited to two business segments with no expansion mentioned.
  • Employees count of 33 is small for a public company.
  • No mention of international market presence beyond Japan.

Opportunities

  • Growing demand for DTx solutions in Health Care sector.
  • Expansion into new disease areas beyond current focus.
  • Potential partnerships with healthcare providers in Japan.

Threats

  • Competition from larger health tech firms in Japan.
  • Regulatory changes in Health Care industry could impact operations.
  • Dependence on Tokyo-To for operations and talent.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.